FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570491737> ?p ?o ?g. }

• W1570491737 endingPage "1279" @default.
• W1570491737 startingPage "1273" @default.
• W1570491737 abstract "The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting.Eligibility included a Zubrod performance status from 0 to 2, no prior gemcitabine or fluoropyrimidine therapy, and normal organ function. Patients received gemcitabine at a dose of 1000 mg/m2 on Days 1, 8, and 15 and capecitabine at a dose of 830 mg/m2 twice daily on Days 1 through 21 on a 28-day cycle with specified dose reductions for baseline renal insufficiency. The primary endpoint was the response rate, which was assessed every 8 weeks. The statistical plan tested the hypothesis that the response rate was 5% versus an alternative of 15%.Sixty patients were enrolled, and 4 of those patients never started treatment. Of the 56 evaluable patients, 79% of patients underwent prior nephrectomy, 75% of patients received prior systemic therapy, and 75% of patients had clear cell histology. Risk stratification revealed that 34%, 43%, and 16% of patients were in Risk Groups 1, 2, and 3, respectively. Toxicity (graded according to the National Cancer Institute's Common Toxicity Criteria [version 2.0]) included Grade 3 or 4 neutropenia in 45% of patients, Grade 2 or greater fatigue in 32% of patients, Grade 2 or greater nausea in 29% of patients, Grade 2 or greater hand-foot reaction in 39% of patients, and Grade 2 or greater diarrhea in 22% of patients. Six patients responded (11%; 95% confidence interval, 4-22%), and the overall median survival was 14.5 months.Gemcitabine plus capecitabine had modest activity in patients with metastatic renal cancer, although the degree of activity and its associated toxicity would not support further evaluation in a Phase III trial of unselected patients. More focused investigations to identify patients most likely to benefit or to enhance activity with additional agents would be reasonable." @default.
• W1570491737 created "2016-06-24" @default.
• W1570491737 creator A5007578304 @default.
• W1570491737 creator A5025529463 @default.
• W1570491737 creator A5028559726 @default.
• W1570491737 creator A5034354367 @default.
• W1570491737 creator A5037431218 @default.
• W1570491737 creator A5053535513 @default.
• W1570491737 creator A5088131964 @default.
• W1570491737 creator A5089516753 @default.
• W1570491737 date "2006-01-01" @default.
• W1570491737 modified "2023-10-16" @default.
• W1570491737 title "A phase II study of gemcitabine and capecitabine in metastatic renal cancer" @default.
• W1570491737 cites W1819301164 @default.
• W1570491737 cites W1942932003 @default.
• W1570491737 cites W1984254136 @default.
• W1570491737 cites W1984400406 @default.
• W1570491737 cites W1986910634 @default.
• W1570491737 cites W1994276424 @default.
• W1570491737 cites W1995176711 @default.
• W1570491737 cites W2016220220 @default.
• W1570491737 cites W2062302016 @default.
• W1570491737 cites W2073311244 @default.
• W1570491737 cites W2078007924 @default.
• W1570491737 cites W2078605907 @default.
• W1570491737 cites W2092806449 @default.
• W1570491737 cites W2105677187 @default.
• W1570491737 cites W2106453307 @default.
• W1570491737 cites W2123914905 @default.
• W1570491737 cites W2125962958 @default.
• W1570491737 cites W2139248078 @default.
• W1570491737 cites W2143813821 @default.
• W1570491737 cites W4253408961 @default.
• W1570491737 doi "https://doi.org/10.1002/cncr.22117" @default.
• W1570491737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16909426" @default.
• W1570491737 hasPublicationYear "2006" @default.
• W1570491737 type Work @default.
• W1570491737 sameAs 1570491737 @default.
• W1570491737 citedByCount "66" @default.
• W1570491737 countsByYear W15704917372012 @default.
• W1570491737 countsByYear W15704917372013 @default.
• W1570491737 countsByYear W15704917372014 @default.
• W1570491737 countsByYear W15704917372015 @default.
• W1570491737 countsByYear W15704917372016 @default.
• W1570491737 countsByYear W15704917372018 @default.
• W1570491737 countsByYear W15704917372019 @default.
• W1570491737 countsByYear W15704917372020 @default.
• W1570491737 countsByYear W15704917372022 @default.
• W1570491737 countsByYear W15704917372023 @default.
• W1570491737 crossrefType "journal-article" @default.
• W1570491737 hasAuthorship W1570491737A5007578304 @default.
• W1570491737 hasAuthorship W1570491737A5025529463 @default.
• W1570491737 hasAuthorship W1570491737A5028559726 @default.
• W1570491737 hasAuthorship W1570491737A5034354367 @default.
• W1570491737 hasAuthorship W1570491737A5037431218 @default.
• W1570491737 hasAuthorship W1570491737A5053535513 @default.
• W1570491737 hasAuthorship W1570491737A5088131964 @default.
• W1570491737 hasAuthorship W1570491737A5089516753 @default.
• W1570491737 hasConcept C121608353 @default.
• W1570491737 hasConcept C126322002 @default.
• W1570491737 hasConcept C141071460 @default.
• W1570491737 hasConcept C143998085 @default.
• W1570491737 hasConcept C203092338 @default.
• W1570491737 hasConcept C2776907518 @default.
• W1570491737 hasConcept C2777063308 @default.
• W1570491737 hasConcept C2777909004 @default.
• W1570491737 hasConcept C2780258809 @default.
• W1570491737 hasConcept C2780580376 @default.
• W1570491737 hasConcept C29730261 @default.
• W1570491737 hasConcept C31760486 @default.
• W1570491737 hasConcept C526805850 @default.
• W1570491737 hasConcept C535046627 @default.
• W1570491737 hasConcept C71924100 @default.
• W1570491737 hasConcept C90924648 @default.
• W1570491737 hasConceptScore W1570491737C121608353 @default.
• W1570491737 hasConceptScore W1570491737C126322002 @default.
• W1570491737 hasConceptScore W1570491737C141071460 @default.
• W1570491737 hasConceptScore W1570491737C143998085 @default.
• W1570491737 hasConceptScore W1570491737C203092338 @default.
• W1570491737 hasConceptScore W1570491737C2776907518 @default.
• W1570491737 hasConceptScore W1570491737C2777063308 @default.
• W1570491737 hasConceptScore W1570491737C2777909004 @default.
• W1570491737 hasConceptScore W1570491737C2780258809 @default.
• W1570491737 hasConceptScore W1570491737C2780580376 @default.
• W1570491737 hasConceptScore W1570491737C29730261 @default.
• W1570491737 hasConceptScore W1570491737C31760486 @default.
• W1570491737 hasConceptScore W1570491737C526805850 @default.
• W1570491737 hasConceptScore W1570491737C535046627 @default.
• W1570491737 hasConceptScore W1570491737C71924100 @default.
• W1570491737 hasConceptScore W1570491737C90924648 @default.
• W1570491737 hasIssue "6" @default.
• W1570491737 hasLocation W15704917371 @default.
• W1570491737 hasLocation W15704917372 @default.
• W1570491737 hasOpenAccess W1570491737 @default.
• W1570491737 hasPrimaryLocation W15704917371 @default.
• W1570491737 hasRelatedWork W1996538874 @default.
• W1570491737 hasRelatedWork W2039108952 @default.
• W1570491737 hasRelatedWork W2068822158 @default.

• next